Novavax, Inc. (NVAX) announced Friday that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid (NVX-CoV2373) into the National Vaccination Program as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
The extended interim authorization was based on data from the pediatric expansion of the Phase 3 PREVxENT-19 trial of 1,799 adolescents aged 12 through 17 years in the U.S., to evaluate the safety and effectiveness of Nuvaxovid.
In the trial, Nuvaxovid achieved its primary endpoint based on neutralizing antibody response and demonstrated clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
Novavax's vaccine is authorized for use in more than 40 markets around the world. In Singapore, the HSA previously granted interim authorization for Nuvaxovid to prevent COVID-19 in adults aged 18 and older in February 2022.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.